HRP970473B1 - 6-o-supstituirani ketolidi antibakterijskog djelovanja - Google Patents

6-o-supstituirani ketolidi antibakterijskog djelovanja

Info

Publication number
HRP970473B1
HRP970473B1 HR970473A HRP970473A HRP970473B1 HR P970473 B1 HRP970473 B1 HR P970473B1 HR 970473 A HR970473 A HR 970473A HR P970473 A HRP970473 A HR P970473A HR P970473 B1 HRP970473 B1 HR P970473B1
Authority
HR
Croatia
Prior art keywords
substituted
alkyl
aryl
heteroaryl
group
Prior art date
Application number
HR970473A
Other languages
English (en)
Inventor
Sun Or Yat
T. Chu Daniel
Ma Zhenkun
J. Plattner Jacob
F. Clark Richard
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27107953&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP970473(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/888,350 external-priority patent/US5866549A/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of HRP970473A2 publication Critical patent/HRP970473A2/hr
Publication of HRP970473B1 publication Critical patent/HRP970473B1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cephalosporin Compounds (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Spoj formuleili njegova farmaceutski prihvatljivasol, naznačen time, daRc predstavlja vodik ili hidroksi zaštitnu skupinu; L predstavlja metilen ilikarbonil, uz uvjet da kada je L metilen, T je -O-,T je izabran iz skupine koja se sastoji od -O-, -NH- i -N(W-Rd)-, gdje je W odsutan ili izabran iz skupine koja se sastoji od -O-, -NH-CO-, -N=CH- i -NH-; te Rd je izabran iz skupine koju čine (1) vodik (2) C1-C6-alkil po izboru supstituiran s jednim ili više supstituenata izabranih iz skupine kojučine (a) aril, (b) supstituirani aril, (c) heteroaril, (d) supstituirani heteroaril, (e) hidroksi, (f) C1-C6-alkoksi, (g) NR7R8 gdje su R7 i R8 zasebno izabrani između vodika i C1-C6-alkil ili se R7 i R8 uzimaju zajedno s atomom dušika na kojeg su vezani dajući 3- do 7- člani prsten koji u slučaju kada je prsten 5- do 7- člani može po izboru sadržavati hetero funkciju izabranu iz skupine koju čine -O-, -NH-, -N(C1-C6-aIkil-)-, -N(aril)-, -N(aril- C1-C6-alkil)-, -N(supstituirani aril-C1-C6-alkil)-, -N(heteroaril), -N(heteroaril- C1-C6-alkil), -N-(supstituirani heteroaril- C1-C6-alki)l i -S- ili -S(O)n-gdje je n 1 ili 2, te (h) -CH2-M-R9gdje je M izabran iz skupine koju čine (i) -C(O)-NH-, (ii) -NH-C(O)-, (iii) -NH-, (iv)-N= (v)-N(CH3)-, (vi) -NH-C(O)-O-, (vii) -NH-C(O)-NH-, (viii) -O-C(O)-NH-, (ix) -O-C(O)-O-, (x)-O-, (xi)-S(O)n-gdje je n0, 1 ili 2, (xii)-C(O)-O-, (xiii) -O-C(O)-, te (xiv) -C(O)-, teR9 je izabran iz skupine koju čine (i) C1-C6-alkil, po izboru supstituiran sa supstituentom izabranim iz skupine koju čine (aa) aril, (bb) supstituirani aril, (cc) heteroaril, te (dd) supstituirani hetereoaril, (ii) aril (iii) supstituirani aril, (iv) heteroaril, (v) supstituirani heteroaril, te (vi) heterocikloalkil, (3) C3-C7-cikloalkil, (4) aril, (5) supstituirani aril, (6) heteroaril, te (7) supstituirani heteroaril, teR je izabran iz skupine koju čine (1) metil supstituiran udjelom izabranim iz skupine koju čine (a)-CN, (b)-F, (c) -CO2R16 gdje R16 je aril supstituiran C1-C3-alkil ili heteroaril supstituiran C1-C3alkil, (d) S(O)nR10 gdje R10 je C1-C3-alkil ili aril supstituirani C1-C3-alkil ili heteroaril supstituirani C1-C3-alkil i n = 0, 1 ili 2, (e) NHC(O)R10, (f) NHC(O)NRnR12 gdje su R11 i R12 svaki zasebno izabrani iz skupine koju čine vodik, C1-C3-alkil, C1-C3-alkil supstituiran s arilom, supstituirani aril, heteoaril ili supstituirani heteroaril, (g) aril, (h) suspstituirani aril, (i) heteroaril, te (j) supstituirani heteroaril, (2) C2-C10-alkil supstituiran s jednim ili više supstituenata izabranih iz skupine koju čine (a) halogen, (b) hidroksi, (c) C1-C3-alkoksi, (d) C1-C3-alkoksi-C1-C3-alkoksi, (e) okso, (f) -N3-, (g) -CHO, (h) -O-SO2-(supstituiran C1-C6-alkil), (i) -NRI3R14 gdje su R13 i R14 izabrani iz skupine koju čine (i) vodik, (ii) C1-C12-alkil, (iii) supstituirani C1-C12-alkil, (iv) C3-C12-alkenil, (v) supstituirani C3-C12-alkeni], (vi) C3-C12-alkinil, (vii) supstituirani C3-C12-alkinil, (viii) aril, (ix) C3-C8-cikloalkil, (x) supstituirani C3
HR970473A 1996-09-04 1997-09-03 6-o-supstituirani ketolidi antibakterijskog djelovanja HRP970473B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70777696A 1996-09-04 1996-09-04
US08/888,350 US5866549A (en) 1996-09-04 1997-07-03 6-O-substituted ketolides having antibacterial activity

Publications (2)

Publication Number Publication Date
HRP970473A2 HRP970473A2 (en) 1998-08-31
HRP970473B1 true HRP970473B1 (hr) 2007-02-28

Family

ID=27107953

Family Applications (5)

Application Number Title Priority Date Filing Date
HR970473A HRP970473B1 (hr) 1996-09-04 1997-09-03 6-o-supstituirani ketolidi antibakterijskog djelovanja
HRP20060277AA HRP20060277B1 (hr) 1996-09-04 2006-08-11 6-0-supstituirani ketolidi antibakterijskog djelovanja
HRP20060276AA HRP20060276B1 (hr) 1996-09-04 2006-08-11 6-0-supstituirani ketolidi antibakterijskog djelovanja
HRP20060278AA HRP20060278B1 (hr) 1996-09-04 2006-08-11 6-0-supstituirani ketolidi antibakterijskog djelovanja
HRP20060275AA HRP20060275B1 (hr) 1996-09-04 2006-08-11 6-0-supstituirani ketolidi antibakterijskog djelovanja

Family Applications After (4)

Application Number Title Priority Date Filing Date
HRP20060277AA HRP20060277B1 (hr) 1996-09-04 2006-08-11 6-0-supstituirani ketolidi antibakterijskog djelovanja
HRP20060276AA HRP20060276B1 (hr) 1996-09-04 2006-08-11 6-0-supstituirani ketolidi antibakterijskog djelovanja
HRP20060278AA HRP20060278B1 (hr) 1996-09-04 2006-08-11 6-0-supstituirani ketolidi antibakterijskog djelovanja
HRP20060275AA HRP20060275B1 (hr) 1996-09-04 2006-08-11 6-0-supstituirani ketolidi antibakterijskog djelovanja

Country Status (28)

Country Link
US (4) US6028181A (hr)
EP (5) EP1291352B1 (hr)
JP (1) JP4597274B2 (hr)
KR (5) KR20050044816A (hr)
CN (4) CN100460415C (hr)
AT (5) ATE296831T1 (hr)
BG (1) BG63547B1 (hr)
BR (1) BR9711661A (hr)
CA (1) CA2263972C (hr)
CZ (1) CZ300106B6 (hr)
DE (5) DE69733439T2 (hr)
DK (5) DK1291352T3 (hr)
ES (5) ES2242813T3 (hr)
HK (1) HK1021537A1 (hr)
HR (5) HRP970473B1 (hr)
HU (1) HU230166B1 (hr)
ID (1) ID19406A (hr)
IL (1) IL128681A0 (hr)
NO (1) NO314230B1 (hr)
NZ (1) NZ334274A (hr)
PL (1) PL188173B1 (hr)
PT (5) PT929563E (hr)
RO (1) RO121473B1 (hr)
RU (1) RU2192427C2 (hr)
SI (1) SI20023B (hr)
SK (5) SK285534B6 (hr)
TR (1) TR199901127T2 (hr)
WO (1) WO1998009978A1 (hr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495348B1 (en) 1993-10-07 2002-12-17 Regents Of The University Of Minnesota Mitomycin biosynthetic gene cluster
UA51730C2 (uk) * 1996-09-04 2002-12-16 Ебботт Лабораторіз 6-o-заміщені кетоліди з антибактеріальною активністю, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб регулювання бактеріальної інфекції у ссавців
AP1060A (en) * 1998-01-02 2002-04-23 Pfizer Prod Inc Novel erythromycin derivatives.
ATE243219T1 (de) 1998-04-24 2003-07-15 Pfizer Prod Inc 9a, 11b-dehydro derivative von 9-oxime-3-keto-6-0-methylerythromycin
US6265202B1 (en) 1998-06-26 2001-07-24 Regents Of The University Of Minnesota DNA encoding methymycin and pikromycin
JP4573925B2 (ja) * 1998-07-09 2010-11-04 アベンティス・ファーマ・ソシエテ・アノニム 新規のエリスロマイシン誘導体、その製造方法及びその薬剤としての使用
FR2792637B1 (fr) * 1999-04-26 2001-06-01 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2780977B1 (fr) * 1998-07-09 2000-09-01 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2785612A1 (fr) * 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
ID28286A (id) 1998-11-03 2001-05-10 Pfizer Prod Inc Antibiotik-antibiotik makrolida baru
JP2002539217A (ja) * 1999-03-15 2002-11-19 アボット・ラボラトリーズ 抗菌活性を有する６−ｏ−置換マクロライド
US6514944B2 (en) 1999-04-16 2003-02-04 Kosan Biosciences, Inc. Macrolide antiinfective agents
US6451768B1 (en) 1999-04-16 2002-09-17 Kosan Biosciences, Inc. Macrolide antiinfective agents
US6939861B2 (en) 1999-04-16 2005-09-06 Kosan Biosciences, Inc. Amido macrolides
CN1241931C (zh) * 1999-04-16 2006-02-15 高山生物科学股份有限公司 大环内酯抗感染药物
EP1181300B1 (en) * 1999-06-07 2003-09-17 Abbott Laboratories 6-o-carbamate ketolide derivatives
US6420535B1 (en) * 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) * 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
US6417366B2 (en) * 1999-06-24 2002-07-09 Abbott Laboratories Preparation of quinoline-substituted carbonate and carbamate derivatives
EP1101769A3 (en) 1999-11-18 2001-10-24 Pfizer Products Inc. Nitrogen containing erythromycin derivatives
US6472372B1 (en) 2000-12-06 2002-10-29 Ortho-Mcneil Pharmaceuticals, Inc. 6-O-Carbamoyl ketolide antibacterials
CA2451391A1 (en) * 2001-07-03 2003-01-16 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
EP1430068A1 (en) 2001-09-17 2004-06-23 Ortho-Mcneil Pharmaceutical, Inc. 6-o-carbamate-11,12-lacto-ketolide antimicrobials
US6673774B2 (en) * 2001-12-03 2004-01-06 Enanta Pharmaceuticals, Inc. 11-O-substituted macrolides and their descladinose derivatives
BR0214748A (pt) 2001-12-05 2004-11-23 Ortho Mcneil Pharm Inc Derivados 6-oacil-cetolidas de eritromicina, úteis como antibacterianos
WO2003068790A2 (en) * 2002-02-13 2003-08-21 Abbott Laboratories Macrolide antibacterial compounds
US6831068B2 (en) * 2002-02-13 2004-12-14 Abbott Laboratories Macrolide antibacterial compounds
US20030162729A1 (en) * 2002-02-13 2003-08-28 Zhenkun Ma Macrolides with activity against methicillin-resistant staphylococcus aureus
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US6995143B2 (en) 2002-02-28 2006-02-07 Basilea Pharmaceutica Ag Macrolides with antibacterial activity
US7910558B2 (en) * 2002-05-13 2011-03-22 Enanta Pharmaceuticals, Inc. Bridged macrocyclic compounds and processes for the preparation thereof
US6841664B2 (en) * 2002-07-25 2005-01-11 Enanra Pharmaceuticals, Inc. 6,11-4-carbon bridged ketolides
US7273853B2 (en) * 2002-05-13 2007-09-25 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
WO2003102010A1 (en) * 2002-05-31 2003-12-11 Janssen Pharmaceutica N.V. 3-descladinosyl-6-o-carbamoyl and 6-o-carbonoyl macrolide antibacterial agents
JPWO2004078771A1 (ja) * 2003-03-07 2006-06-08 大正製薬株式会社 ２−フルオロ−６−ｏ−置換ケトライド誘導体
ES2552682T3 (es) * 2003-03-10 2015-12-01 Merck Sharp & Dohme Corp. Agentes antibacterianos novedosos
CA2523541A1 (en) * 2003-04-25 2004-11-11 Chiron Corporation Novel ketolide derivatives
US6790835B1 (en) * 2003-06-05 2004-09-14 Enanta Pharmaceuticals, Inc. Bicyclic macrolide derivatives
US20040254126A1 (en) * 2003-06-05 2004-12-16 Yao-Ling Qiu 11-12 Bicyclic erythromycin derivatives
US20050101548A1 (en) * 2003-09-12 2005-05-12 Xiaodong Lin Antimicrobial derivatives
GB0327720D0 (en) * 2003-11-28 2003-12-31 Biotica Tech Ltd Erythromycins and process for their preparation
US7414030B2 (en) * 2004-01-07 2008-08-19 Enanta Pharmaceuticals, Inc. 6-11 Bicyclic erythromycin derivatives
WO2005070113A2 (en) * 2004-01-09 2005-08-04 Enanta Pharmaceuticals, Inc. 9n-substituted 6-11 bicyclic erythromycin derivatives
US7384921B2 (en) * 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
WO2006024741A2 (fr) * 2004-07-30 2006-03-09 Palumed S.A. Molecules hybrides qa ou q est une aminoquinoleine et a est un residu antibiotique, leur synthese et leurs utilisations en tant qu'agent antibacterien
FR2874922A1 (fr) * 2004-07-30 2006-03-10 Palumed Sa Molecules hybrides qa ou q est une aminoquinoleine et a est un residu antibiotique, leur synthese et leurs utilisations en tant qu'agent antibacterien
WO2006065743A2 (en) * 2004-12-13 2006-06-22 Enanta Pharmaceuticals, Inc. Tetracylic bicyclolides
PL1836211T3 (pl) 2004-12-21 2010-07-30 Pfizer Prod Inc Makrolidy
US20060252710A1 (en) * 2005-05-04 2006-11-09 Guoqiang Wang 6-11 Bridged oxime erythromycin derivatives
US7384922B2 (en) * 2005-05-04 2008-06-10 Enanta Pharmaceuticals, Inc. 6-11 bridged oxime erythromycin derivatives
US7517859B2 (en) * 2005-05-04 2009-04-14 Enanta Pharmaceuticals, Inc. Spirocyclic bicyclolides
US8097708B2 (en) 2006-02-07 2012-01-17 Taisho Pharmaceutical Co., Ltd. 10a-Azalide compound
JP2010501541A (ja) 2006-08-24 2010-01-21 ウォックハート リサーチ センター 抗菌活性を有する新規マクロライド及びケトライド
US8293715B2 (en) 2007-08-06 2012-10-23 Taisho Pharmaceutical Co., Ltd. 10a-Azalide compound crosslinked at 10a- and 12-positions
WO2009039177A1 (en) * 2007-09-17 2009-03-26 Enanta Pharmaceuticals, Inc. 6, 11-bicycloides: bridged biaryl macrolide derivatives
US8354383B2 (en) * 2007-09-17 2013-01-15 Enanta Pharmaceuticals, Inc. 6,11-bridged biaryl macrolides
US8273720B2 (en) * 2007-09-17 2012-09-25 Enanta Pharmaceuticals, Inc. 6,11-bicyclolides: bridged biaryl macrolide derivatives
EP2214484A4 (en) * 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS
TW200946109A (en) * 2008-05-09 2009-11-16 Enanta Pharm Inc Anti-bacterial activity of 9-hydroxy derivatives 6, 11-bicyclolides
US8299035B2 (en) 2008-05-15 2012-10-30 Taisho Pharmaceutucal Co., Ltd. 10a-azalide compound having 4-membered ring structure
CN105616437A (zh) * 2008-10-24 2016-06-01 森普拉制药公司 使用含三唑的大环内酯的生物防御
NZ596628A (en) 2009-05-27 2013-03-28 Ketolide compounds having antimicrobial activity
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
EP2475253B1 (en) 2009-09-10 2016-10-26 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and mac diseases
CA2793884C (en) 2010-03-22 2019-09-10 Cempra Pharmaceuticals, Inc. Crystalline forms of a macrolide, and uses therefor
DK2571506T3 (en) 2010-05-20 2017-08-28 Cempra Pharmaceuticals Inc PROCEDURES FOR THE MANUFACTURE OF MACROLIDES AND KETOLIDES AND INTERMEDIATES
US8796474B1 (en) 2010-08-23 2014-08-05 Rutgers, The State University Of New Jersey Macrolide compounds and methods and intermediates useful for their preparation
JP6042334B2 (ja) 2010-09-10 2016-12-14 センプラ ファーマシューティカルズ，インコーポレイテッド 疾患治療のための水素結合形成フルオロケトライド
US9175031B2 (en) 2010-12-09 2015-11-03 Wockhardt Limited Ketolide compounds
AR085286A1 (es) 2011-02-21 2013-09-18 Taisho Pharmaceutical Co Ltd Derivado de macrolido sustituido en la posicion c-4
CN103619849B (zh) 2011-03-01 2016-05-25 沃克哈特有限公司 酮内酯中间体的制备方法
CN103619863B (zh) 2011-03-22 2016-03-16 沃克哈特有限公司 酮内酯化合物的制备方法
CN102766181A (zh) * 2011-05-06 2012-11-07 上海医药工业研究院 6-o-取代的红霉素衍生物的制备方法
CN102766089A (zh) * 2011-05-06 2012-11-07 上海医药工业研究院 3-(3-喹啉基)-2-丙烯-1-卤代物及其制备方法
AU2013239696C1 (en) 2012-03-27 2018-11-29 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
JP5857008B2 (ja) * 2012-08-20 2016-02-10 大正製薬株式会社 Ｃ−４”位置換マクロライド誘導体を含有する医薬
GB201217310D0 (en) 2012-09-27 2012-11-14 C10 Pharma As Compounds
EP2968801B1 (en) 2013-03-14 2018-09-26 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
US9751908B2 (en) 2013-03-15 2017-09-05 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
AR102810A1 (es) 2014-08-18 2017-03-29 Taisho Pharmaceutical Co Ltd Derivado de macrólido sustituido en la posición c-4
JP2019533669A (ja) 2016-10-04 2019-11-21 バイオファーマティ ソシエテ アノニム 抗菌活性を有するケトライド
EP3589327A4 (en) * 2017-03-03 2022-04-06 Synovo GmbH NOVEL ANTI-INFECTION AND ANTI-INFLAMMATORY COMPOUNDS
CN109942653B (zh) * 2019-02-27 2021-06-25 北京理工大学 一种红霉素衍生物及其制备方法
WO2021113357A1 (en) * 2019-12-02 2021-06-10 AliquantumRx, Inc. Salts and polymorphs of cethromycin for the treatment of disease salts and polymorphs of cethromycin
CN113817008B (zh) * 2021-07-15 2023-05-23 湖州师范学院 新型琥珀酰基十六元大环内酯的制备方法及用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960000434B1 (ko) * 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
KR930702369A (ko) * 1990-10-15 1993-09-08 우에노 아키라 에리쓰로마이신 또는 그의 유도체의 2'위치 수식 화합물
IL99995A (en) * 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
US5403923A (en) * 1990-11-28 1995-04-04 Taisho Pharmaceutical Co., Ltd. 6-0-methylerythromycin A derivatives
WO1993013663A1 (en) * 1992-01-17 1993-07-22 Abbott Laboratories Method of directing biosynthesis of specific polyketides
US5523399A (en) * 1991-12-27 1996-06-04 Taisho Pharmaceutical Co., Ltd. 5-O-desosaminylerythronolide derivatives
CA2093303C (en) * 1992-04-09 1998-11-24 Abraham Araya Aluminosilicates
AU662420B2 (en) * 1992-04-22 1995-08-31 Taisho Pharmaceutical Co., Ltd. 5-O-desosaminylerythronolide A derivative
FR2697524B1 (fr) * 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5527780A (en) * 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2702480B1 (fr) * 1993-03-09 1995-04-28 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2713226B1 (fr) * 1993-12-03 1996-01-05 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2718450B1 (fr) * 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) * 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2732023B1 (fr) * 1995-03-22 1997-04-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2732684B1 (fr) * 1995-04-06 1997-04-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2738571B1 (fr) * 1995-09-11 1997-10-17 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-0-methyl- erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
ES2218604T3 (es) * 1995-11-08 2004-11-16 Abbott Laboratories Derivados triciclicos de eritromicina.
UA51730C2 (uk) * 1996-09-04 2002-12-16 Ебботт Лабораторіз 6-o-заміщені кетоліди з антибактеріальною активністю, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб регулювання бактеріальної інфекції у ссавців
WO1998018808A1 (en) * 1996-10-31 1998-05-07 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
US6171807B1 (en) * 1996-11-13 2001-01-09 Associates Of Cape Cod, Inc. Detection and quantitation of endotoxin by fluorescence polarization

Also Published As

Publication number Publication date
HK1021537A1 (en) 2000-06-16
KR100576988B1 (ko) 2006-05-10
KR20050043993A (ko) 2005-05-11
NO991022L (no) 1999-05-03
ES2244716T3 (es) 2005-12-16
DE69733370D1 (de) 2005-06-30
CN1680420A (zh) 2005-10-12
BG103292A (en) 1999-12-30
DK1291350T3 (da) 2005-09-26
EP1291352A1 (en) 2003-03-12
DK1291351T3 (da) 2005-10-24
KR20050044816A (ko) 2005-05-12
DK1291352T3 (da) 2005-09-19
HRP20060275B1 (hr) 2014-04-11
EP1291351B1 (en) 2005-07-13
ES2242813T3 (es) 2005-11-16
CN100441591C (zh) 2008-12-10
US6075133A (en) 2000-06-13
SI20023A (sl) 2000-02-29
PT1291352E (pt) 2005-09-30
ATE296832T1 (de) 2005-06-15
BG63547B1 (bg) 2002-04-30
KR100610043B1 (ko) 2006-08-08
CA2263972C (en) 2008-01-29
ATE299508T1 (de) 2005-07-15
HRP20060277B1 (hr) 2014-04-11
AU729348B2 (en) 2001-02-01
DE69733422T2 (de) 2006-05-04
CN1680419A (zh) 2005-10-12
PT1291351E (pt) 2005-11-30
DE69733439D1 (de) 2005-07-07
SK285535B6 (sk) 2007-03-01
US6028181A (en) 2000-02-22
CZ300106B6 (cs) 2009-02-11
EP1291353A1 (en) 2003-03-12
DE69733422D1 (de) 2005-07-07
DK1291353T3 (da) 2005-10-03
NO991022D0 (no) 1999-03-02
ID19406A (id) 1998-07-09
KR100568455B1 (ko) 2006-04-07
HUP9902869A2 (hu) 2000-02-28
CA2263972A1 (en) 1998-03-12
JP2001500855A (ja) 2001-01-23
SI20023B (en) 2001-02-28
EP1291351A1 (en) 2003-03-12
KR100523679B1 (ko) 2005-10-26
DE69733723T2 (de) 2006-04-20
HU230166B1 (hu) 2015-09-28
ATE296308T1 (de) 2005-06-15
HRP20060275A2 (hr) 2007-10-31
HRP20060277A2 (hr) 2007-10-31
NZ334274A (en) 2001-02-23
ES2242983T3 (es) 2005-11-16
AU4178097A (en) 1998-03-26
RO121473B1 (ro) 2007-06-29
ATE296831T1 (de) 2005-06-15
DK0929563T3 (da) 2005-10-03
KR20000068435A (ko) 2000-11-25
SK285536B6 (sk) 2007-03-01
DE69733723D1 (de) 2005-08-18
EP1291352B1 (en) 2005-05-25
HRP20060278A2 (hr) 2007-10-31
KR20050043994A (ko) 2005-05-11
DE69733369D1 (de) 2005-06-30
HRP20060278B1 (hr) 2014-04-11
ES2242811T3 (es) 2005-11-16
EP1291353B1 (en) 2005-06-01
DE69733370T2 (de) 2006-02-02
ES2242812T3 (es) 2005-11-16
TR199901127T2 (xx) 1999-07-21
DE69733439T2 (de) 2006-05-04
PL332009A1 (en) 1999-08-16
EP1291350B1 (en) 2005-05-25
RU2192427C2 (ru) 2002-11-10
SK285533B6 (sk) 2007-03-01
HUP9902869A3 (en) 2001-04-28
EP1291350A1 (en) 2003-03-12
BR9711661A (pt) 1999-08-24
SK286181B6 (sk) 2008-04-07
NO314230B1 (no) 2003-02-17
CZ68599A3 (cs) 1999-08-11
PT929563E (pt) 2005-10-31
SK28699A3 (en) 2000-03-13
SK285534B6 (sk) 2007-03-01
HRP20060276B1 (hr) 2014-04-25
PT1291353E (pt) 2005-10-31
EP0929563B1 (en) 2005-06-01
DE69733369T2 (de) 2006-01-26
ATE296307T1 (de) 2005-06-15
JP4597274B2 (ja) 2010-12-15
CN1237183A (zh) 1999-12-01
US6147197A (en) 2000-11-14
CN1273475C (zh) 2006-09-06
CN100460415C (zh) 2009-02-11
IL128681A0 (en) 2000-01-31
USRE39591E1 (en) 2007-04-24
HRP970473A2 (en) 1998-08-31
EP0929563A1 (en) 1999-07-21
CN1680418A (zh) 2005-10-12
PL188173B1 (pl) 2004-12-31
WO1998009978A1 (en) 1998-03-12
HRP20060276A2 (hr) 2007-10-31
KR20050044815A (ko) 2005-05-12
PT1291350E (pt) 2005-09-30

Similar Documents

Publication Publication Date Title
HRP970473B1 (hr) 6-o-supstituirani ketolidi antibakterijskog djelovanja
GB2381456A (en) Antimicrobial agent
DE69330776D1 (de) Polymergebundene Paclitaxel-derivate
GB2200908A (en) Spiro-oxazine compounds
DE69416306D1 (de) Sphingoglycolipid und verwendung davon
CA2173150A1 (en) Novel peptide derivatives
CA2115355A1 (en) Novel tetrapeptide derivative
DE69619139D1 (de) Ein amonenaustauscherharz enthaltende tabletten
Bottalico et al. Cytochalasins: structure-activity relationships
AR015994A1 (es) Derivados de cetolidos 2-halo-6-o-sustituidos, composiciones farmaceuticas que los contienen, su uso para la manufactura de un medicamento y procesos parasu preparacion
FI923170A0 (fi) Spicamycinderivat och anvaendning av dem.
DE69132580D1 (de) 7-Acyl-3-(substituierte carbamoyloxy) Cephem Verbindungen, Verfahren zu ihrer Herstellung und Anwendung
GB1456674A (en) Neomycin derivatives
GB1530643A (en) Aminoglycosides
CO4960636A1 (es) Derivados de eritromicina 3-descladinosa 6-0-substituidos
IE41221L (en) Pyrazinemethanols
NZ334980A (en) Aminomethylene derivatives with ultraviolet absorption capability
GB1418399A (en) Antibiotic derivatives
JPS5455047A (en) Vinyl chloride resin composition
AU2953697A (en) Vitamin d analogs and methods of preparing these compounds
GB1418701A (en) Acylated derivatives of substituted piperazines and polymeric compositions stabilized thereby
CA2149826A1 (en) 7-glycosyloxybenzopyran derivative and antiallergic agent containing the derivative as active ingredient
NO922608L (no) Nye cefalosporinforbindelser og fremgangsmaater til deres fremstillin
ES387208A1 (es) Procedimiento para la preparacion de nuevos cardenolidram- nosidos.
DK0384890T3 (da) Middel til beskyttelse af planter mod sygdomme

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: ABBVIE INC., US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20160901

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20170903